CMV Linked to Increased Inflammation and Aging in HIV Patients, Study Suggests
People living with HIV may face accelerated aging and heightened inflammation due to cytomegalovirus (CMV) infection, according to a study by the European AIDS Treatment Group. The research, published in *Clinical Infectious Diseases*, found that CMV contributes to chronic immune activation, a key driver of aging-related complications in HIV patients.
Understanding CMV and HIV: A Dual Challenge
CMV, a common herpesvirus, typically causes mild symptoms in healthy individuals but can lead to severe illness in immunocompromised people, including those with HIV. The European AIDS Treatment Group’s analysis of 1,200 HIV-positive participants revealed that those with CMV had significantly higher levels of inflammatory markers, such as C-reactive protein and interleukin-6, compared to those without the virus.
“CMV persistence is associated with prolonged immune activation, which may explain why some HIV patients experience age-related conditions like cardiovascular disease or cognitive decline earlier than expected,” said Dr. Maria Zuniga, a co-author of the study and infectious disease specialist at the University of Barcelona.
Implications for Treatment and Research
The findings highlight the potential for targeting CMV as a strategy to reduce inflammation in HIV care. Current antiretroviral therapies (ART) control HIV replication but do not eliminate CMV, which can remain latent and reactivate. Researchers are exploring whether antiviral drugs like valganciclovir could mitigate CMV’s role in immune aging.
“If we can manage CMV more effectively, it might reduce the burden of chronic inflammation, improving long-term outcomes for HIV patients,” said Dr. James Smith, an HIV researcher at the National Institutes of Health, who was not involved in the study. “However, more trials are needed to confirm these benefits.”
What This Means for HIV Patients
For individuals living with HIV, the study underscores the importance of monitoring CMV status, especially as they age. While routine CMV testing is not yet standard in HIV care, experts suggest that patients with unexplained inflammation or aging-related symptoms should discuss CMV screening with their providers.
“This research adds to growing evidence that HIV management must address not just viral load but also co-infections like CMV,” said Dr. Linda-Gail Bekker, CEO of the South African AIDS Vaccine Initiative. “A holistic approach could slow the aging process and reduce comorbidities.”
Future Directions in HIV and CMV Research
Scientists are now investigating whether CMV-targeted therapies could complement ART. Early-phase trials are underway to assess the safety and efficacy of long-term antiviral treatment in reducing inflammation. Additionally, researchers are exploring biomarkers to identify HIV patients most at risk for CMV-related aging complications.
“The next step is to determine whether interrupting CMV’s role in immune activation translates to real-world benefits, like fewer heart attacks or better cognitive function,” said Dr. Zuniga. “This could reshape how we think about HIV care in the aging population.”
As the HIV-positive population ages, understanding the interplay between CMV and aging will be critical. While the study does not prove causation, it provides a compelling rationale for further research into CMV as a modifiable factor in HIV-related health outcomes.